1. Name Of The Medicinal Product
Cetirizine 1mg/ml Oral Solution.
2. Qualitative And Quantitative Composition
Each 10ml of solution contains 10mg of cetirizine dihydrochloride
For a full list of excipients see Section 6.1 List of excipients
3. Pharmaceutical Form
Oral solution
Clear solution
4. Clinical Particulars
4.1 Therapeutic Indications
In adults and children 2 years of age and above
For the symptomatic treatment of seasonal allergic rhinitis (hayfever), perennial rhinitis and chronic idiopathic urticaria in adults and children aged 6 years and over, and for seasonal rhinitis in children aged between 2 and 6 years.
4.2 Posology And Method Of Administration
Adults and Children over 12 years: 10mg (10ml oral suspension 2 full spoons) once a day.
Children between 6 and 12 years: 5 mg (5 ml a full spoonful) twice a day.
Children between 2 and 6 years for seasonal rhinitis (hayfever): (2.5 ml oral solution twice daily) a half spoonful twice a day.
At present there are insufficient clinical data to recommend use of cetirizine in children under 2 years of age.
Patients with moderate to severe renal impairment
The dosing intervals must be individualized according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in ml/min is needed. The CLcr (ml/min) may be estimated from serum creatinine (mg/dl) determination using the following formula:
Dosing adjustments for adult patients with impaired renal function
Group
|
Creatinine clearance (ml/min)
|
Dosage and frequency
|
Normal
|
|
10 mg once daily
|
Mild
|
50 - 79
|
10 mg once daily
|
Moderate
|
30 - 49
|
5 mg once daily
|
Severe
|
< 30
|
5 mg once every 2 days
|
End-stage renal disease -
|
< 10
|
contraindicated
|
Patients undergoing dialysis
|
|
|
In paediatric patients who suffer from renal impairment, the dose will have to be adjusted on an individual basis taking into account the renal clearance of the patient and his body weight.
Patients with hepatic impairment
No dose adjustment is required in patients with solely hepatic impairment.
Patients with hepatic impairment and renal impairment
Adjustment of the dose is recommended (see Patients with renal impairment above).
Cetirizine dihydrochloride is contraindicated in patients with severe renal impairment. In patients with moderate renal impairment the dose should be adjusted to 5 mg (1/2 tablet per day). Caution should be exercised in patients with mild to moderate renal impairment or impaired liver function (see section 4.4 Special warnings and precautions for use).
Elderly subjects
Data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function is normal.
4.3 Contraindications
- History of hypersensitivity to any of the constituents of the formulation, to hydroxyzine or to any piperazine derivatives.
- Patients with severe renal impairment at less than 10 ml/min creatinine clearance
- Patients with rare hereditary problems of fructose intolerance should not take cetirizine 1 mg/ml oral solution.
4.4 Special Warnings And Precautions For Use
At therapeutic doses, no clinically significant interactions have been demonstrated with alcohol (blood alcohol level of 0.5 g/L). Although precaution is recommended if taken concomitantly with alcohol.
Caution in epileptic patients and patients' at risk of convulsions is recommended.
The use of the product is not recommended in children aged less than 2 years (see section 4.2)..
Methyl parahydroxybenzoate and propyl parahydroxybenzoate included in the 10 mg/ml oral drops and in the 1 mg/ml oral solution may cause allergic reactions (possibly delayed).
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
Due to the pharmacokinetic, pharmacodynamic and tolerance profile of cetirizine, no interactions are expected with this antihistamine. Neither the pharmacodynamic nor significant pharmacokinetic interaction was reported in drug-drug interactions studies performed, notably with pseudoephedrine or theophylline (400 mg/day).
The extent of absorption of the cetirizine is not reduced with food, although the rate of absorption is decreased.
4.6 Pregnancy And Lactation
Pregnancy
For cetirizine very rare clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development. Caution should be exercised when prescribing to pregnant women.
Lactation
Cetirizine is excreted in human milk at concentrations representing 0.25 to 0.90 those measured in plasma, depending on sampling time after administration. Therefore, caution should be exercised when prescribing cetirizine to lactating women.
4.7 Effects On Ability To Drive And Use Machines
Objective measurements of driving ability, sleep problems and assembly line performance have not demonstrated any clinically relevant effects at the recommended dose of 10 mg.
Patients intending to drive, or engage in potentially hazardous activities or operating machinery should not exceed the recommended dose and should take their response to the medicinal product into account.
In sensitive patients, concurrent use with alcohol or other CNS depressants may cause additional reductions in alertness and impairment of performance.
4.8 Undesirable Effects
Clinical studies have shown that cetirizine at the recommended dosage has minor adverse effects on the CNS, including somnolence, fatigue, dizziness and headache. In some cases, paradoxical CNS stimulation has been reported.
Although cetirizine is a selective antagonist of peripheral H1-receptors and is relatively free of anticholinergic activity, isolated cases of micturition difficulty, eye accommodation disorders and dry mouth have been reported.
Instances of abnormal hepatic function with elevated hepatic enzymes accompanied by elevated bilirubin have been reported. Mostly this resolves upon discontinuation of the drug.
Clinical trials
Double blind controlled clinical trials comparing cetirizine to placebo or other antihistamines at the recommended dosage (10 mg daily for cetirizine), of which quantified safety data are available, included more than 3200 subjects exposed to cetirizine.
From this pooling, the following adverse reactions were reported for cetirizine 10 mg in the placebo-controlled trials at rates of 1.0% or greater:
Adverse reactions
(WHO-ART)
|
Cetirizine 10 mg
(n= 3260)
|
Placebo
(n = 3061)
|
Body as a whole - general disorders
Fatigue
|
1.63%
|
0.95%
|
Central and peripheral nervous system disorders
Dizziness
Headache
|
1.10%
7.42%
|
0.98%
8.07 %
|
Gastro-intestinal system disorders
Abdominal pain
Dry mouth
Nausea
|
0.98%
2.09%
1.07%
|
1.08%
0.82%
1.14%
|
Psychiatric disorders
Somnolence
|
9.63%
|
5.00%
|
Respiratory system disorders
Pharyngitis
|
1.29%
|
1.34%
|
Although statistically more common than under placebo, somnolence was mild to moderate in the majority of cases. Objective tests as demonstrated by other studies have demonstrated that usual daily activities are unaffected at the recommended daily dose in healthy young volunteers.
Adverse reactions at rates of 1% or greater in children aged from 6 months to 12 years, included in placebo-controlled clinical trials are:
Adverse reactions
(WHO-ART)
|
Cetirizine
(n= 1656)
|
Placebo
(n = 1294)
|
Gastro-intestinal system disorders
Diarrhoea
|
1.0%
|
0.6%
|
Psychiatric disorders
Somnolence
|
1.8%
|
1.4%
|
Respiratory system disorders
Rhinitis
|
1.4%
|
1.1%
|
Body as a whole - general disorders
Fatigue
|
1.0%
|
0.3%
|
Post-marketing experience
In addition to the adverse reactions reported during clinical studies and listed above, the following undesirable effects have been reported in post-marketing experience.
Undesirable effects are described according to MedDRA System Organ Class and by estimated frequency based on post-marketing experience.
Frequencies are defined as follows: Very common (
Blood and lymphatic disorders
|
|
Very rare:
|
thrombocytopenia
|
Immune system disorders
|
|
Rare:
|
hypersensitivity
|
Very rare:
|
anaphylactic shock
|
Psychiatric disorders
|
|
Uncommon:
|
agitation
|
Rare:
|
aggression, confusion, depression, hallucination, insomnia
|
Very rare:
|
tics
|
Nervous system disorders
|
|
Uncommon:
|
paraesthesia
|
Rare:
|
convulsions
|
Very rare:
|
dysgeusia, dyskinesia, dystonia, syncope, tremor
|
Not known:
|
amnesia, memory impairment
|
Eye disorders
|
|
Very rare:
|
accommodation disorder, blurred vision, oculogyration
|
Cardiac disorders
|
|
Rare:
|
tachycardia
|
Gastro-intestinal disorders
|
|
Uncommon:
|
diarrhea
|
Hepatobiliary disorders
|
|
Rare:
|
hepatic function abnormal (increased transaminases, alkaline phosphatase, γ-GT and bilirubin)
|
Skin and subcutaneous tissue disorders
|
|
Uncommon:
|
pruritus, rash
|
Rare:
|
urticaria
|
Very rare:
|
angioneurotic oedema, fixed drug eruption
|
Renal and urinary disorders
|
|
Very rare:
|
dysuria, enuresis
|
General disorders and administration site conditions
|
|
Uncommon:
|
asthenia, malaise
|
Rare:
|
oedema
|
Investigations
|
|
Rare:
|
weight increased
|
4.9 Overdose
a) Symptoms
Symptoms observed after an overdose of cetirizine are mainly associated with CNS effects or with effects that could suggest an anticholinergic effect.
Adverse events reported after an intake of at least 5 times the recommended daily dose are: Adverse events reported after an intake of at least 5 times the recommended daily dose are: confusion, diarrhoea, dizziness, fatigue, headache, malaise, mydriasis, pruritus, restlessness, sedation, somnolence, stupor, tachycardia, tremor, and urinary retention.
b) Management
There is no known specific antidote to cetirizine.
Gastric lavage should be considered following ingestion of a short occurrence.
Cetirizine is not effectively removed by dialysis.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Pharmacotherapeutic group: Piperazine derivatives, ATC code: R06A E07
Cetirizine a metabolite of hydroxyzine, is a potent and selective antagonist of peripheral H1-receptors. In vitro receptor binding studies have shown no measurable affinity for other than H1-receptors.
In addition to its anti-H1 effect, cetirizine displays an anti-allergic activities: at a dose of 10 mg once or twice daily, it inhibits the late phase recruitment of eosinophils, in the skin and conjunctiva of atopic subjects submitted to allergen challenge.
Studies in healthy volunteers show that cetirizine, at doses of 5 and 10 mg strongly inhibits the wheal and flare reactions induced by very high concentrations of histamine in the skin but this correlation with efficacy has not been established.
In a 35-day study in children aged 5 to 12, no tolerance to the antihistaminic effect (suppression of wheal and flare) of cetirizine was found. When a treatment with cetirizine is stopped after repeated administration, the skin recovers its normal reactivity to histamine within 3 days.
In a six-week, placebo-controlled study of 186 patients with allergic rhinitis and concomitant mild to moderate asthma, cetirizine 10 mg once daily improved rhinitis symptoms and do not alter pulmonary function. This study supports the safety of administering cetirizine to allergic patients with mild to moderate asthma.
In a placebo-controlled study, cetirizine given at the high daily dose of 60 mg for seven days did not cause statistically significant prolongation of QT interval.
At the recommended dosage, cetirizine improves the quality of life of patients with perennial and seasonal allergic rhinitis.
5.2 Pharmacokinetic Properties
The steady- state peak plasma concentrations of approximately 300 ng/ml is achieved within 1.0 ± 0.5 h. No accumulation is observed for cetirizine following daily doses of 10 mg for 10 days. The distribution of pharmacokinetic parameters such as peak plasma concentration (Cmax) and area under curve (AUC), is unimodal in volunteers.
The extent of absorption of cetirizine is not reduced with food, although the rate of absorption is decreased. The extent of bioavailability is similar whether the cetirizine its given as a solution, capsules or tablet.
The apparent volume of distribution is 0.50 l/kg. The plasma protein binding of cetirizine is 93 ± 0.3 %. Cetirizine does not modify the protein binding of warfarin.
Cetirizine does not undergo extensive first pass metabolism, approximately two thirds of the dose are excreted unchanged in urine. The terminal half-life is approximately 10 hours.
Cetirizine exhibits linear kinetics over the range of 5 to 60 mg.
Special populations:
Elderly: Following a single 10 mg oral dose the half-life increased by about 50 % and clearance decreased by 40 % in 16 elderly subjects compared to the normal subjects. The decrease in cetirizine clearance in these elderly volunteers appeared to be related to their decreased renal function.
Children, infants and toddlers: The half-life of cetirizine was about 6 hours in children aged 6-12 years and 5 hours in children 2-6 years. In infants and toddlers aged 6 to 24 months its reduced to 3.1 hours.
Renal impaired patients: The pharmacokinetics of the drug were similar in patients with mild impairment (creatinine clearance < 40 ml/min) and healthy volunteers. Patients with moderate renal impairment had a 3-fold increase in half-life and 70 % decrease in clearance compared to healthy volunteers.
Patients on haemodialysis (creatinine clearance less than 7 ml/min) given a single oral 10 mg dose of cetirizine had a 3-fold increase in half-life and a 70 % decrease in clearance compared to normal patients. Cetirizine was poorly cleared by haemodialysis. A dosing adjustment is necessary in patients with moderate or severe renal impairment (see section 4.2).
Hepatically impaired patients: Patients with chronic liver diseases (hepatocellular, cholestatic and biliary cirrhosis) given 10 or 20 mg of cetirizine as a single dose had a 50 % increase in half-life along with a 40 % decrease in clearance compared to healthy subjects.
Dosing adjustment is only necessary in hepatic impairment patients if concomitant renal impairment is present.
5.3 Preclinical Safety Data
Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Liquid sorbitol (non-crystallising)
Glycerol
Propylene glycol
Methyl parahydroxybenzoate
Propyl parahydroxybenzoate
Sodium acetate
Glacial acetic acid
Saccharin sodium
Mixed Fruit Flavour ID 21533 (which contains vanillin, orange oil, ethyl vanillin, amyl acetate, amyl butyrate, amyl propionate, ethyl butyrate, ethyl propionate, citral, allyl heptylate, linalool, terpeneol, lemon oil, geraniol, butyric acid and propylene glycol)
Raspberry flavour 249 (which contains raspberry aldehyde, amyl acetate, amyl butyrate, ethyl acetate, ethyl butyrate, hexanyl butyrate, alpha ionone, geraniol, clove oil, cinnamon oil, orris oil, geranium oil and propylene glycol)
Purified water
6.2 Incompatibilities
Not applicable.
6.3 Shelf Life
Unopened: 24 months.
After first opening: 3 months.
6.4 Special Precautions For Storage
Do not store above 25°C. Store in the original package.
6.5 Nature And Contents Of Container
Type III Amber glass bottles fitted with EPE lined child resistant closures or amber PET containers fitted with EPE lined child resistant closures.
6.6 Special Precautions For Disposal And Other Handling
Not applicable.
7. Marketing Authorisation Holder
Sandoz Ltd
Frimley Business Park,
Frimley,
Camberley,
Surrey,
GU16 7SR.
United Kingdom
8. Marketing Authorisation Number(S)
PL 04416/0410
9. Date Of First Authorisation/Renewal Of The Authorisation
09/02/2009
10. Date Of Revision Of The Text
July 2011
